References
- Lacour M, van de Heyning PH, Novotny M, Tighilet B. Betahistine in the treatment of Ménière's disease. Neuropsych Dis Treat 2007; 3: 1–12
- Mira E. Improving the quality of life in patients with vestibular disorders: the role of medical treatments and physical rehabilitation. Int J Clin Pract 2008; 62: 109–14
- Brandt T. Management of vestibular disorders. J Neurol 2000; 247: 491–9
- Ganança MM, Mangabeira Albernaz PL, Caovilla HH, Ganança FF. Drug therapy of dizziness, hypoacusia and tinnitus due to neurotological disorders. Vertigo, hypoacusia and tinnitus due to central disequilibrium, CF Claussen, MV Kirtane, D Schneider. Medicin and Pharmacie, Hamburg 1994; 617–23
- Rascol O, Hain TC, Brefel C, Benazet M, Clanet M, Montastruc JL. Antivertigo medications and drug-induced vertigo. A pharmacological review. Drugs 1995; 50: 777–91
- Lacour M. Restoration of vestibular function: basic aspects and practical advances for rehabilitation. Curr Med Res Opin 2006; 22: 1651–9
- Lacour M, Sterkers O. Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action. CNS Drugs 2001; 15: 853–70
- Valli P. Betahistine reduces the resting firing rate of vestibular receptors in the frog. Acta Otolaryngol 2000; 544: 8–10
- Dziadziola JK, Laurikainen EL, Rachel JD, Quirk WS. Betahistine increases vestibular blood flow. Otolaryngol Head Neck Surg 1999; 120: 400–5
- Arrang JM, Garbarg M, Quach TT, Dam Trung Tuong M, Yeramian E, Schwartz JC. Actions of betahistine at histamine receptors in the brain. Eur J Pharmacol 1985; 111: 73–84
- Ganança MM, Caovilla HH, Munhoz MSL, Ganança CF, Silva MLG, Serafini F, et al. Otimizando o componente farmacológico da terapia integrada da vertigem. Rev Bras Otorrinolaringol 2007; 73: 12–18
- Mira E, Guidetti G, Ghilardi L, Fattori B, Malannino N, Maiolino L, et al. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. Eur Arch Otorhinolaryngol 2003; 260: 73–7
- Claes J, van de Heyning PH. A review of medical treatment for Ménière's disease. Acta Otolaryngol Suppl 2000; 544: 34–9
- Albera R, Ciuffolotti R, Di Cicco M, De Benedittis G, Grazioli I, Melzi G, et al. Double-blind, randomized, multicenter study comparing the effect of betahistine and flunarizine on the dizziness handicap in patients with recurrent vestibular vertigo. Acta Otolaryngol 2003; 123: 588–93
- Yardley L, Kirby S. Evaluation of booklet-based self-management of symptoms in Ménières disease: a randomized controlled trial. Psychosom Med 2006; 68: 762–9
- van Dulmen S, Sluijs E, van Dijk L, de Ridder D, Heerdink R, Bensing J. Patient adherence to medical treatment: a review of reviews. BMC Health Serv Res 2007; 7: 55
- Claxton AJ, Cramer J, Pierce C. A systematic review of the association between dosing regimens and medical compliance. Clin Ther 2001; 23: 1296–310
- Tran Ba Huy P, Meyrand MF. Betahistine dihydrochloride in 2 or 3 doses per day: randomised, comparative, open trial in 2 groups of patients suffering from recurrent vertigo. J Fr Oto-Rhino-Laryngol 1992; 41(Suppl 3)1–4
- Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Menière's disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. Otolaryngol Head Neck Surg 1995;113:181–5.
- Colletti V. Medical treatment in Ménière's disease: avoiding vestibular neurectomy and facilitating postoperative compensation. Acta Otolaryngol Suppl 2000; 544: 27–33